lap

LAP is a highly efficient and biocompatible radical photoinitiator used to initiate radical chain polymerisation and synthesise polymeric materials under light irradiation. The primary wavelength for light absorption and polymerisation initiation is 405 nm. LAP concentrations ≥3.4 mmol/L and the radicals it generates exhibit cytotoxicity towards M-1 mouse renal collecting duct cells.

SDZ 281-977 is a derivative of Lavendustin A, an EGF receptor tyrosine kinase inhibitor.

Anti-LAP Antibody is a human-derived antibody expressed in CHO cells, targeting LAP. It possesses huIgG2 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. For the isotype control, refer to HumanIgG2kappa, Isotype Control.

Lupus autoantigen peptide (LAP), a derivative of the autoantigen La found in systemic lupus erythematosus (SLE) patients, spans amino acids 11-28 of La and functions as an antiviral peptide. It primarily blocks the hepatitis C virus (HCV) from interacting with internal ribosome entry site (IRES) trans-acting factors (ITAFs), notably the polypyrimidine tract-binding protein (PTB) and poly(rC)-binding protein 2 (PCBP2). In a Huh7 cell-based reporter assay, LAP at a concentration of 60 µM effectively hampers HCV IRES-mediated translation, a process reversible by adding recombinant forms of PTB and PCBP2.

Azelaprag (Example 263.0) is a candidate active molecule (EC50= 0.32 nM) for an apelin receptor agonist. Azelaprag can be used to treat nervous system diseases, cardiovascular diseases.

Olaparib (KU0059436) is a small molecule inhibitor of PARP1/PARP2 (IC50=5/1 nM), with weak inhibitory activity against PARP tankyrase-1 (IC50=1.5 μM), and is selective and orally active. Olaparib exhibits autophagy and mitochondrial autophagy activation activity.

Veliflapon is an orally active and selective inhibitor of 5-lipoxygenase activating protein (FLAP). Veliflapon inhibits the synthesis of the leukotrienes B4 and C4.

(2R,3S)-N-(4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide is an Apelin receptor agonist with an EC50 for Apelin receptors of 0.012 µM.(2R,3S)-N-(4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-(5- methylpyrimidin-2-yl)butane-2-sulfonamide is used in the treatment of heart failure, atherosclerosis, obesity, diabetes mellitus, amyotrophic lateral sclerosis, coronary artery disease, hypertension, stroke and myocardial infarction.

Rilapine (Rilapinum) is an antipsychotic compound that shows high affinity for 5-HT6 receptors and can be used to study neurological disorders.

Lapisteride (CS-891) a steroidal 5α-reductase inhibitor is used to treat benign prostatic hyperplasia (BPH) and androgenetic alopecia and may be effective in preventing or treating AGA .

Vilaprisan (BAY 1002670) is a novel orally available and selective progesterone receptor modulator (SPRM) with antiproliferative activity against uterine fibroids (UF) and can be used for the study of uterine fibroids.

Goxalapladib(GSK 677116) is a small molecule compound that can be used to treat cardiovascular risks associated with atherosclerosis.

Laprafylline is a xanthine compound with inhibitory effects on bronchoconstriction in vivo and antitumor activity.Laprafylline acts as a competitive serotonergic antagonist at low concentrations, and inhibits constriction induced by hist at high difficulties.

Alaproclate is a non-competitive NMDA receptor antagonist and a new selective 5-HT uptake inhibitor for the study of depression and dementia.

(Z)-Tenilapine is trans-Tenilapine, cis-Tenilapine has sedative activity.

Tenilapine is a neuroleptic compound that can be used to study atypical antipsychotics.

Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression.

Lapatinib ditosylate (Lapatinib tosilate) monohydrate is a tyrosine kinase receptor inhibitor used in the therapy of advanced breast cancer and other solid tumors. Lapatinib ditosylate monohydrate therapy is associated with transient elevations in serum aminotransferase levels and rare instances of clinically apparent acute liver injury.

Enalapril IMpurity B ((+)-N-[1-(S)-Ethoxycarbonxyl-3-phenylpropyl]-L-alanine) is Moexipril intermediate and is the main metabolite of Imidapril.

Lappaconitine ((+)-Lappaconitine), isolated from Aconitum sinomontanum Nakai, was characterized as an analgesic.

Polaprezinc is an bioavailable chelate comprised of zinc and L-carnosine, known for its gastrointestinal protective properties, as well as its anti-ulcer, antioxidant, and anti-inflammatory effects.

Lapatinib Ditosylate (Tykerb ditosylate) is an effective EGFR and ErbB2 inhibitor (IC50: 10.8/9.2 nM for EGFR/ErbB2).

Enalapril Maleate (MK-421 Maleate), an angiotensin-converting enzyme (ACE) inhibitor, is utilized in the treatment of hypertension, chronic heart failure , and diabetic nephropathy.

Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor with potential anti-inflammatory activity. It mitigates statin-induced toxicity in human skeletal muscle cells and protects guinea pigs from simvastatin-induced myotoxicity, useful for research on hypercholesterolemia and HMG-CoA reductase deficiency.